The World Health Organization (WHO) is enrolling patients in a clinical trial in the Democratic Republic of the Congo (DRC) to test potential treatments for Bundibugyo virus disease (BVD), a rare form of Ebola. Sources report that the PARTNERS trial opens patient enrolment in the Ituri region and broader DRC response area, with the first patient enrolled as early as Thursday, following an accelerated setup timeline after the outbreak was declared a public health emergency of international concern in May. The trial evaluates two antiviral therapies—monoclonal antibody MBP134 and remdesivir—both as standalone options and in combination, to determine whether they improve survival and whether combined therapy offers additional benefit. WHO and partner organizations conduct and coordinate the study, including DRC and international research institutions. All reporting notes that there are currently no approved treatments for BVD. Patients in the trial receive supportive care and close follow-up, including monitoring for at least 28 days after enrolment. Multiple outlets also reference the scale of the outbreak to date, with hundreds of deaths and more than a thousand confirmed cases in DRC, and ongoing security and response challenges in some treatment settings.